Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016:917:55-76.
doi: 10.1007/978-3-319-32805-8_4.

Generation of Recombinant Antibodies Against Toxins and Viruses by Phage Display for Diagnostics and Therapy

Affiliations
Review

Generation of Recombinant Antibodies Against Toxins and Viruses by Phage Display for Diagnostics and Therapy

Tobias Unkauf et al. Adv Exp Med Biol. 2016.

Abstract

Antibody phage display is an in vitro technology to generate recombinant antibodies. In particular for pathogens like viruses or toxins, antibody phage display is an alternative to hybridoma technology, since it circumvents the limitations of the immune system. Phage display allows the generation of human antibodies from naive antibody gene libraries when either immunized patients are not available or immunization is not ethically feasible. This technology also allows the construction of immune libraries to select in vivo affinity matured antibodies if immunized patients or animals are available.In this review, we describe the generation of human and human-like antibodies from naive antibody gene libraries and antibodies from immune antibody gene libraries. Furthermore, we give an overview about phage display derived recombinant antibodies against viruses and toxins for diagnostics and therapy.

Keywords: Antibody; Antibody engineering; Pathogen; Phage display; Therapy; Toxins; Viruses; scFv.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23:1147–1157. doi: 10.1038/nbt1137. - DOI - PubMed
    1. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;9:52. doi: 10.1186/1471-2474-9-52. - DOI - PMC - PubMed
    1. Amersdorfer P, Wong C, Chen S, et al. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun. 1997;65:3743–3752. - PMC - PubMed
    1. Amersdorfer P, Wong C, Smith T, et al. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine. 2002;20:1640–1648. doi: 10.1016/S0264-410X(01)00482-0. - DOI - PubMed
    1. Amaro I, Riaño-Umbarila L, Becerril B, Possani LD. Isolation and characterization of a human antibody fragment specific for Ts1 toxin from Tityus serrulatus scorpion. Immunol Lett. 2011;139:73–79. doi: 10.1016/j.imlet.2011.05.002. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources